Hepatitis C News

Treatment with either pegylated interferon with ribavirin or direct-acting antivirals for hepatitis C correlated with a significantly lower risk for cardiovascular disease, especially among patients who achieved sustained virologic response, according to a study published in Gastroenterology.

Mavyret demonstrated 97% sustained virologic response in a large, real-world cohort of patients with hepatitis C over an 8-week course and extended 12-week to 16-week courses, according to recently published data.

The Medicines Patent Pool signed a royalty-free license agreement with AbbVie to enable quality-assured manufacturers to develop and sell generic medicines including Mavyret, according to a press release.

Results from a retrospective review of patients infected with hepatitis C in childhood revealed that those with perinatal infection developed cirrhosis earlier than other risk groups, according to a recently published study.

SAN FRANCISCO — In this exclusive video perspective from The Liver Meeting 2018, Monica Konerman, MD, director of the Michigan Medicine NAFLD Clinic, discusses results of a study that found opioid use to be twice as common among patients with chronic liver disease compared with other common chronic diseases.

SAN FRANCISCO — Preemptive administration of pangenotypic direct-acting antiviral therapy resulted in rapid viral suppression of hepatitis C in patients without HCV who received a heart transplantation with an HCV-positive organ, according to data presented at The Liver Meeting 2018.

SAN FRANCISCO — Mavyret yielded nearly perfect SVR rates after 8 weeks of therapy in compensated cirrhosis with HCV, according to data presented at The Liver Meeting 2018.

SAN FRANCISCO — U.S. states in the Appalachian region demonstrated increased rates of hepatitis B among women despite overall national rates of acute and chronic HBV remaining stable or declining among women and children, according to data presented at The Liver Meeting 2018.

SAN FRANCISCO — Individuals with hepatitis C who underwent DAA therapy experienced significant reductions in both hepatocellular carcinoma and decompensation risk compared with untreated patients, according to data presented at The Liver Meeting 2018.

SAN FRANCISCO — A telemedicine program brought high levels of satisfaction and proved cost effective in patients with hepatitis C in a Spanish prison, according to data presented at The Liver Meeting 2018.